Relationship of the 2011 global initiative for chronic obstructive lung disease strategy to clinically relevant outcomes in individuals with α1-antitrypsin deficiency

Annals of the American Thoracic Society

Volumn 11, Issue 6, 2014, Pages 859-864

  Pillai, Anilkumar P ^a   Turner, Alice M ^a,b,c   Stockley, Robert A ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Exacerbations; Lung function decline; Mortality

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE REGISTRY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HIGH RISK POPULATION; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; ALPHA 1-ANTITRYPSIN DEFICIENCY; COMPLICATION; EPIDEMIOLOGY; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENT DISEASE; RETROSPECTIVE STUDY; SURVIVAL RATE; TIME; TRENDS; UNITED KINGDOM;

ALPHA 1-ANTITRYPSIN DEFICIENCY; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; GREAT BRITAIN; HUMANS; LUNG; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 84911900083     PISSN: 23296933     EISSN: 23256621     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201311-380OC     Document Type: Article

References (22)

1. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-365.
2. Pillai AP, Turner AM, Stockley RA. Global Initiative for Chronic Obstructive Lung Disease 2011 symptom/risk assessment in α1-antitrypsin deficiency. Chest 2013;144:1152-1162.
3. Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, Nordestgaard BG. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 2012;186:975-981.
4. Dawkins PA, Dowson LJ, Guest PJ, Stockley RA. Predictors of mortality in alpha1-antitrypsin deficiency. Thorax 2003;58:1020-1026.
5. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, Skovgaard LT, Kok-Jensen A, Rudolphus A, Seersholm N, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999;160:1468-1472.
6. Laurell CB. Genetic variants of alpha 1-antitrypsin. Vox Sang 1965;10:363-364.
7. Dowson LJ, Guest PJ, Stockley RA. Longitudinal changes in physiological, radiological, and health status measurements in alpha (1)-antitrypsin de ficiency and factors associated with decline. Am J Respir Crit Care Med 2001;164:1805-1809.
8. Nishimura M, Makita H, Nagai K, Konno S, Nasuhara Y, Hasegawa M, Shimizu K, Betsuyaku T, Ito YM, Fuke S, et al .; Hokkaido COPD Cohort Study Investigators. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:44-52.
9. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-1422.
10. Needham M, Stockley RA. Exacerbations in {alpha}1-antitrypsin de ficiency. Eur Repir J 2005;25:992-1000.
11. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-1554.
12. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789.
13. Chapman KR, Stockley RA, Dawkins PA, Wilkes MM, Navickis RJ. Augmentation therapy for alpha1 antitrypsin deficiency: a metaanalysis. COPD 2009;6:177-184.
14. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
15. Dawkins PA, Dawkins CL, Wood AM, Nightingale PG, Stockley JA, Stockley RA. Rate of progression of lung function impairment in alpha1-antitrypsin deficiency. Eur Respir J 2009;33:1338-1344.
16. Parr DG, Stoel BC, Stolk J, Stockley RA. Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences lung function impairment. Am J Respir Crit Care Med 2004;170:1172-1178.
17. Miyamoto K, Aida A, Nishimura M, Aiba M, Kira S, Kawakami Y; The Respiratory Failure Research Group in Japan. Gender effect on prognosis of patients receiving long-term home oxygen therapy. Am J Respir Crit Care Med 1995;152:972-976.
18. Sunyer J, Antó JM, McFarlane D, Domingo A, Tobías A, Barceló MA, Múnoz A. Sex differences in mortality of people who visited emergency rooms for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:851-856.
19. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-852.
20. Holme J, Stockley RA. Radiologic and clinical features of COPD patients with discordant pulmonary physiology: lessons from alpha1-antitrypsin deficiency. Chest 2007;132:909-915.
21. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-1138.
22. Burrows B. An overview of obstructive lung diseases. Med Clin North Am 1981;65:455-471.